2019-19779. Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Notice.

    SUMMARY:

    The Food and Drug Administration (FDA) is publishing a Start Printed Page 48152list of information collections that have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Ila S. Mizrachi, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-7726, PRAStaff@fda.hhs.gov.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    The following is a list of FDA information collections recently approved by OMB under section 3507 of the Paperwork Reduction Act of 1995 (44 U.S.C. 3507). The OMB control number and expiration date of OMB approval for each information collection are shown in table 1. Copies of the supporting statements for the information collections are available on the internet at http://www.reginfo.gov/​public/​do/​PRAMain. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

    Table 1—List of Information Collections Approved By OMB

    Title of collectionOMB control No.Date approval expires
    Disease Awareness and Prescription Drug Promotion on Television0910-08748/31/2021
    Reporting Associated with New Animal Drug Applications and Veterinary Master Files0910-00327/31/2022
    Substances Generally Recognized as Safe: Notification Procedure0910-03427/31/2022
    Establishing and Maintaining Lists of U.S. Product Manufacturers/Processors with Interest in Exporting CFSAN-Regulated Products0910-05097/31/2022
    Oversight of Clinical Investigations; A Risk-Based Approach to Monitoring0910-07337/31/2022
    Safety Labeling Changes; Implementation of the Federal Food, Drug, and Cosmetic Act0910-07347/31/2022
    Accreditation of Third Party Certification Bodies to Conduct Food Safety Audits and Issue Certifications0910-07507/31/2022
    Mitigation Strategies to Protect Food Against Intentional Adulteration0910-08127/31/2022
    Standards for the Growing, Harvesting, Packaging, and Holding of Produce for Human Consumption0910-08167/31/2022
    De Novo Classification Process (Evaluation of Automatic Class III Designation)0910-08448/31/2022
    Start Signature

    Dated: September 6, 2019.

    Lowell J. Schiller,

    Principal Associate Commissioner for Policy.

    End Signature End Supplemental Information

    [FR Doc. 2019-19779 Filed 9-11-19; 8:45 am]

    BILLING CODE 4164-01-P

Document Information

Published:
09/12/2019
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
2019-19779
Pages:
48151-48152 (2 pages)
Docket Numbers:
Docket Nos. FDA-2018-N-3516, FDA 2019-N-0482, FDA-2012-N-0021, FDA-2018-N-4042, FDA-2011-D-0597, FDA-2018-N-4735, FDA-2019-N-0721, FDA-2013-N-1425, FDA-2018-D-3631, and FDA-2011-D-0689
PDF File:
2019-19779.pdf
Supporting Documents:
» Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals
» Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Oversight of Clinical Investigations: A Risk-Based Approach to Monitoring
» Agency Information Collection Activities; Proposed Collection; Comment Request; Oversight of Clinical Investigations: A Risk-Based Approach to Monitoring
» Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals
» Agency Information Collection Activities; Submission for Office of Management and Budget Review; Guidance for Industry on Oversight of Clinical Investigations: A Risk-Based Approach to Monitoring
» Agency Information Collection Activities; Proposed Collection; Comment Request; Guidance for Industry on Oversight of Clinical Investigations: A Risk-Based Approach To Monitoring
» Guidance for Industry on Oversight of Clinical Investigations--A Risk-Based Approach to Monitoring
» Guidance for Industry on Oversight of Clinical Investigations--A Risk-Based Approach to Monitoring; Availability
» Agency Information Collection Activities; Proposals, Submissions, and Approvals: Draft Guidance for Industry; Oversight of Clinical Investigations; A Risk-Based Approach to Monitoring
» Draft Guidance for Industry; Oversight of Clinical Investigations; A Risk-Based Approach to Monitoring